178 related articles for article (PubMed ID: 14555309)
21. Megakaryopoiesis in chronic myeloproliferative diseases. A morphometric evaluation with special emphasis on primary thrombocythemia.
Thiele J; Funke S; Holgado S; Choritz H; Georgii A
Anal Quant Cytol; 1984 Sep; 6(3):155-67. PubMed ID: 6594964
[TBL] [Abstract][Full Text] [Related]
22. Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis.
Chott A; Gisslinger H; Thiele J; Fritz E; Linkesch W; Radaszkiewicz T; Ludwig H
Br J Haematol; 1990 Jan; 74(1):10-6. PubMed ID: 2310690
[TBL] [Abstract][Full Text] [Related]
23. Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis--features of significance for the diagnosis of primary (essential) thrombocythaemia.
Thiele J; Schneider G; Hoeppner B; Wienhold S; Zankovich R; Fischer R
Virchows Arch A Pathol Anat Histopathol; 1988; 413(5):407-17. PubMed ID: 3140482
[TBL] [Abstract][Full Text] [Related]
24. Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms.
Espasandin YR; Glembotsky AC; Grodzielski M; Lev PR; Goette NP; Molinas FC; Marta RF; Heller PG
J Thromb Haemost; 2015 Apr; 13(4):631-42. PubMed ID: 25604267
[TBL] [Abstract][Full Text] [Related]
25. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
Silver RT
Leukemia; 2005 Jan; 19(1):39-43. PubMed ID: 15510207
[TBL] [Abstract][Full Text] [Related]
26. The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy.
D'adda M; Micheletti M; Drera M; Ferrari S; Rossi G
Leuk Lymphoma; 2008 Nov; 49(11):2216-8. PubMed ID: 19021067
[No Abstract] [Full Text] [Related]
27. Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: an immunohistochemical study of 127 patients.
Thiele J; Kvasnicka HM; Beelen DW; Flucke U; Spoer C; Paperno S; Leder LD; Schaefer UW
Mod Pathol; 2001 Feb; 14(2):129-38. PubMed ID: 11235904
[TBL] [Abstract][Full Text] [Related]
28. [Emperipolesis in megakaryocytes in patients with thrombocytosis in the course of myeloproliferative disorders].
Bobik R; Podolak-Dawidziak M; Kiełbiński M; Jeleń M; Wróbel T
Acta Haematol Pol; 1995; 26(2):179-83. PubMed ID: 7653223
[TBL] [Abstract][Full Text] [Related]
29. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia.
Yoon SY; Li CY; Mesa RA; Tefferi A
Br J Haematol; 1999 Sep; 106(3):682-8. PubMed ID: 10468856
[TBL] [Abstract][Full Text] [Related]
30. The frequency and significance of megakaryocytic emperipolesis in myeloproliferative and reactive states.
Cashell AW; Buss DH
Ann Hematol; 1992 Jun; 64(6):273-6. PubMed ID: 1637881
[TBL] [Abstract][Full Text] [Related]
31. [The use of anagrelide to treat thrombocytosis in connection with the chronic myeloproliferative disease].
Jantunen E; Penttilä K; Kuittinen T; Nousiainen T
Duodecim; 2006; 122(4):453-7. PubMed ID: 16623100
[No Abstract] [Full Text] [Related]
32. Megakaryocytopoiesis in idiopathic thrombocytopenic purpura: a morphometric and immunohistochemical study on bone marrow biopsies with special emphasis on precursor cells.
Thiele J; von Ammers E; Wagner S; Degel C; Fisher R
Hematol Pathol; 1991; 5(2):75-82. PubMed ID: 1894584
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers.
Abe Andes W; Noveck RJ; Fleming JS
Thromb Haemost; 1984 Dec; 52(3):325-8. PubMed ID: 6531755
[TBL] [Abstract][Full Text] [Related]
34. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia.
Tomer A
Blood; 2002 Mar; 99(5):1602-9. PubMed ID: 11861274
[TBL] [Abstract][Full Text] [Related]
35. [Megakaryocytopoiesis in myeloproliferative disorders].
Podolak-Dawidziak M
Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
[No Abstract] [Full Text] [Related]
36. Myelodysplastic syndromes: immunohistochemical and morphometric evaluation of proliferative activity in erythropoiesis and endoreduplicative capacity of megakaryocytes.
Thiele J; Hoffmann I; Bertsch HP; Fischer R
Virchows Arch A Pathol Anat Histopathol; 1993; 423(1):33-8. PubMed ID: 8105604
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies.
Thiele J; Kvasnicka HM; Diehl V; Fischer R; Michiels J
Leuk Lymphoma; 1999 Apr; 33(3-4):207-18. PubMed ID: 10221501
[TBL] [Abstract][Full Text] [Related]
38. Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders.
Ludwig H; Linkesch W; Gisslinger H; Fritz E; Sinzinger H; Radaszkiewicz T; Chott A; Flener R; Micksche M
Cancer Immunol Immunother; 1987; 25(3):266-73. PubMed ID: 3677127
[TBL] [Abstract][Full Text] [Related]
39. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.
Thiele J; Kvasnicka HM
Ann Hematol; 2003 Mar; 82(3):148-52. PubMed ID: 12634946
[TBL] [Abstract][Full Text] [Related]
40. Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction.
Ahluwalia M; Donovan H; Singh N; Butcher L; Erusalimsky JD
J Thromb Haemost; 2010 Oct; 8(10):2252-61. PubMed ID: 20586925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
